国际眼科纵览 ›› 2025, Vol. 49 ›› Issue (1): 68-74.doi: 10.3760/cma.j.cn115500-20240518-01012

• 综述 • 上一篇    下一篇

间充质干细胞治疗眼表疾病的研究进展

任淑婷1 谢小东2   

  1. 1 新疆医科大学,乌鲁木齐 830054;2 新疆维吾尔自治区人民医院眼科医学诊疗中心,乌鲁木齐 830001
  • 收稿日期:2024-05-18 出版日期:2025-02-22 发布日期:2025-02-20
  • 通讯作者: 谢小东,Email:thinkpad.xj@foxmail.com
  • 基金资助:
    新疆维吾尔自治区人民医院院内基金(GXBZX-2023005)

Research advancement of mesenchymal stem cells in the treatment of ocular diseases

Ren Shuting1, Xie Xiaodong2   

  1. 1 Xinjiang Medical University, Urumqi 830054, China; 2 Ophthalmic Center, the People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
  • Received:2024-05-18 Online:2025-02-22 Published:2025-02-20
  • Contact: Xie Xiaodong, Email: thinkpad.xj@foxmail.com
  • Supported by:
    Internal Fund of Xinjiang Uygur Autonomous Region People's Hospital (GXBZX-2023005)

摘要: 间充质干细胞是一种多能干细胞,具有抗炎、免疫调节、损伤修复和组织再生的特性,并能产生细胞外囊泡。源自间充质干细胞的细胞外囊泡不仅保留了干细胞的治疗特性,还具备便于储存和运输、以及低致癌风险等优点。在眼表疾病的模型中,间充质干细胞可以通过调节免疫反应和抑制炎症进展,促进角膜组织再生,还能增加泪腺腺泡数量,从而缓解水液缺乏型干眼的症状。对于翼状胬肉,它们通过抑制成纤维细胞迁移,减少组织侵袭能力,并通过重编程巨噬细胞来抑制炎症反应,缓解眼移植物抗宿主病患者的眼部不适。此外,间充质干细胞还有助于缓解过敏性结膜炎症状和改善眼部化学伤的愈后。虽然目前已有临床实验验证间充质干细胞对眼表疾病的疗效,但证据仍不充分。(国际眼科纵览,2025, 49:68-74)

关键词: 间充质干细胞, 细胞外囊泡, 眼表, 干眼, 翼状胬肉

Abstract: Mesenchymal stem cells (MSCs) are multipotent stem cells with anti-inflammatory, immunomodulatory, damage repair, and tissue regeneration properties, and they have the capability to produce extracellular vesicles. These vesicles derived from MSCs retain similar therapeutic characteristics as the stem cells themselves and offer advantages such as easier storage and transport, as well as a lower risk of carcinogenesis. In  models of ocular surface disease, mesenchymal stem cells can alleviate the symptoms of hydration-deficient dry eye by modulating the immune response and inhibiting the progression of inflammation, promoting corneal tissue regeneration, and increasing the number of lacrimal acinars. For pterygium, MSCs reduce tissue invasiveness by inhibiting fibroblast migration. Additionally, they relieve ocular discomfort in patients with graft-versus-host disease by reprogramming macrophages to suppress inflammation. Furthermore, MSCs help in alleviating symptoms of allergic conjunctivitis and improving the prognosis of chemical eye injuries. Although clinical trials are underway to validate the efficacy of mesenchymal stem cells in ocular surface diseases, the evidence is still insufficient. (Int Rev Ophthalmol, 2025, 49:  68-74)

Key words: mesenchymal stem cells, extracellular vesicles, ocular surface, dry eye disease, pterygium